Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Ophthalmology
Published in: BMC Ophthalmology 1/2018

Open Access 01-12-2018 | Case report

Highly suspected primary intraocular lymphoma in a patient with rheumatoid arthritis treated with etanercept: a case report

Authors: Woo Keun Song, Ah Ran Cho, Young Hee Yoon

Published in: BMC Ophthalmology | Issue 1/2018

Login to get access

Abstract

Background

To describe a case of highly suspected primary intraocular lymphoma (PIOL) in a patient using etanercept for the treatment of rheumatoid arthritis.

Case presentation

A 50-year-old female patient presented with decreased vision in her left eye that lasted for a week. She had a 15-year history of seropositive rheumatoid arthritis (RA), and had been taking weekly etanercept for the preceding 8 months. Funduscopic examination and SD-OCT showed a swollen ellipsoid zone (EZ) and a retinal pigment epithelium (RPE) irregularity of the right eye. We also noted EZ disruption and a RPE irregularity in the left eye. As subretinal infiltration was aggravated in the right eye after the initial treatment, we completed a vitrectomy. Vitreous cytology revealed PIOL with positive CD20 immunostaining. She was treated with serial intravitreal methotrexate injections and systemic chemotherapy. After the treatment, subretinal infiltration and subRPE deposits were decreased in the right eye with no evidence of recurrence in either eye.

Conclusions

This case suggests a potential relationship between immunosuppression with anti-TNFα medication, and increased risk for lymphoma, especially in patients with underlying rheumatologic disorders and especially in patients with suspected chronic refractory uveitis.
Literature
1.
Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Catrina AI, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692–701.CrossRefPubMed
2.
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–85.CrossRefPubMed
3.
Georgakopoulou EA, Andreadis D, Arvanitidis E, Loumou P. Biologic agents and oral diseases--an update on clinical applications. Acta Dermatovenerol Croat. 2013;21:24–34.PubMed
4.
Mocellin S, Pilati P, Nitti D. Towards the development of tumor necrosis factor (TNF) sensitizers: making TNF work against cancer. Curr Pharm Des. 2007;1:537–51.CrossRef
5.
Davis JL, Viciana AL, Ruiz P. Diagnosis of intraocular lymphoma by flow cytometry. Am J Ophthalmol. 1997;124:362–72.CrossRefPubMed
6.
Kimura K, Usui Y, Goto H. Japanese intraocular lymphoma study group. Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma. Jpn J Ophthalmol. 2012;56:383–9.CrossRefPubMed
7.
Missotten T, Tielemans D, Bromberg JE, et al. Multicolor flowcytometric immunophenotyping is a valuable tool for detection of intraocular lymphoma. Ophthalmology. 2013;120:991–6.CrossRefPubMed
8.
Cassoux N, Giron A, Bodaghi B, et al. IL-10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma. Invest Ophthalmol Vis Sci. 2007;48:3252–9.CrossRef
9.
Costopoulos M, Touitou V, Golmard JL, et al. ISOLD: a new highly sensitive interleukin score for intraocular lymphoma diagnosis. Ophthalmology. 2016;123:1626–8.CrossRefPubMed
10.
Mehta M, Rasheed RA, Duker J, et al. Vitreous evaluation: a diagnostic challenge. Ophthalmology. 2015;122:531–7.CrossRefPubMed
11.
Langerak AW, Groenen PJ, Bruggemann M, et al. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia. 2012;26:2159–71.CrossRefPubMedPubMedCentral
12.
Coupland SE, Hummel M, Muller HH, et al. Molecular analysis of immunoglobulin genes in primary intraocular lymphoma. Invest Ophthalmol Vis Sci. 2005;46:3507–14.CrossRefPubMed
13.
Chan CC, Rubenstein JL, Coupland SE, et al. Primary vitreoretinal lymphoma: a report from an international primary central nervous system lymphoma collaborative group symposium. Oncologist. 2011;16:1589–99.CrossRefPubMedPubMedCentral
14.
Peer J, Hochberg FH, Foster CS. Clinical review: treatment of vitreoretinal lymphoma. Ocul Immunol Inflamm. 2009;17:299–306.CrossRef
15.
16.
Yeh S, Weichel ED, Faia LJ, et al. 25-gauge transconjunctival sutureless vit-rectomy for the diagnosis of intraocular lymphoma. Br J Ophthalmol. 2010;94:633–8.CrossRefPubMedPubMedCentral
17.
Kievit W, Fransen J, Adang EM, den Broeder AA, Bernelot Moens HJ, Visser H, et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch rheumatoid arthritis monitoring register. Rheumatology (Oxford). 2011;50:196–203.CrossRef
18.
Mercer LK, et al. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology biologics register for rheumatoid arthritis. Ann Rheum Dis. 2017 Mar;76(3):497–503.CrossRefPubMedPubMedCentral
19.
Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275-85.
20.
Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898-908.
21.
Nagata K, Inaba T, Kinoshita S. CD5-positive primary intraocular B-cell lymphoma arising during methotrexate and tumor necrosis factor inhibitor treatment. Case Rep Ophthalmol. 2015;6(3):301–6.CrossRefPubMedPubMedCentral
Metadata
Title
Highly suspected primary intraocular lymphoma in a patient with rheumatoid arthritis treated with etanercept: a case report
Authors
Woo Keun Song
Ah Ran Cho
Young Hee Yoon
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Ophthalmology / Issue 1/2018
Electronic ISSN: 1471-2415
DOI
https://doi.org/10.1186/s12886-018-0832-0

Other articles of this Issue 1/2018

BMC Ophthalmology 1/2018 Go to the issue

Research article

Clinical outcome observation of the embolization of orbital vascular malformation with medical glue under direct intra-operative view

Research article

Social-economic analysis of patients with Sjogren’s syndrome dry eye in East China: a cross-sectional study

Research article

Combined 23-gauge transconjunctival vitrectomy and scleral fixation of intraocular lens without conjunctival dissection in managing lens complications

Research article

Investigation of the anti-cataractogenic mechanisms of curcumin through in vivo and in vitro studies

Case report

Femtosecond laser-assisted removal of an intracorneal chestnut, a case report

Case report

Surgical removal of submacular perfluorocarbon liquid with a 38-gauge flexible cannula combined with internal limiting membrane peeling and intravitreal air tamponade: a case series